Immobilized human CTLA-4 at 0.5 μg/ml (50 μL/well) can bind to Ipilimumab with a linear range of 0.305 ng/ml-5 μg/ml.
Product Details
Product Details
Product Specification
| Host | Human |
| Synonyms | Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CD152 |
| Accession | P16410 |
| Clone Number | S-SC014 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG1,k |
| Application | Blocking of CTLA-4 signaling Functional assays |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| ELISA | 0.305-5000 ng/ml |
Background
Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Picture
Picture
ELISA
